Deciphera Pharmaceuticals, a Waltham, MA-based clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, closed a $75m Series B financing.
The round was led by New Leaf Venture Partners with participation from existing investors. In conjunction with the funding, Liam Ratcliffe, M.D., Ph.D., Managing Director at New Leaf Venture Partners, will join Deciphera’s board of directors.
The company intends to use the funds to advance its pipeline of proprietary switch control kinase inhibitors through multiple key clinical milestones.
Led by Michael D. Taylor, Ph.D., President and CEO, Deciphera Pharmaceuticals designs kinase inhibitor therapies that simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread.
The company’s product pipeline includes four product candidates in Phase 1 clinical development including altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK inhibitor; DCC-2618, a pan-KIT inhibitor; rebastinib, a TIE2 kinase inhibitor; and a pan-RAF inhibitor (LY-3009120) being developed by partner Eli Lilly. In addition, DCC-3014, a selective inhibitor of CSF1R, is currently in preclinical development.